
Prometa pilot program loses funding
amid questions over effectiveness
By Kari Huus Reporter
MSNBC
updated 4:49 a.m. CT, Fri., Jan. 11, 2008
A trial of a controversial drug cocktail designed to treat meth and cocaine addiction has been halted after an audit found that the treatment’s success rate had been “greatly exaggerated.”
The action was a major blow to Hythiam Inc., which licenses the “Prometa protocol” to private doctors and stands to benefit financially if it can gain access to public funding of drug treatment across the country. Coupled with subsequent media reports that public officials who championed the pilot program owned stock in Hythiam, the news sent the company’s shares plummeting from more than $8 a share in October to about $2.75 this week.

Read more LifeLube blog coverage of the controversial and unproven Prometa protocol here.
For even more background on Prometa, check out the info page on Crystal Breaks here.
No comments:
Post a Comment